Pharmaceutical

LakeShore commences BLA submission to DRAP for rabies vaccine

LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority of Pakistan (DRAP) seeking conditional approval for its PIKA Rabies Vaccine for post-exposure prophylaxis (PEP).

Nov 9, 2024 - 06:00
LakeShore commences BLA submission to DRAP for rabies vaccine
LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority of Pakistan (DRAP) seeking conditional approval for its PIKA Rabies Vaccine for post-exposure prophylaxis (PEP).
Read the original article

Tags:

Previous Article

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets

Next Article

AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

Jul 13, 2023

STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics

STAT+: USDA to push food producers to substantiate clai...

Jun 16, 2023

STAT+: Most large U.S. funders of clinical research have poor transparency policies, analysis finds

STAT+: Most large U.S. funders of clinical research hav...

Apr 17, 2023